PD-1/PD-L1 inhibitors, PMID: 26047524
Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab, PMID: 28717238
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis, PMID: 29093678
Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy, PMID: 28431010
Blockade of the PD-1 axis alone is not sufficient to activate HIV-1 virion production from CD4+ T cells of individuals on suppressive ART, PMID: 30682108
Clinical Trials Investigating Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer, PMID: 27457350
Immunologic checkpoints blockade in renal cell, prostate, and urothelial malignancies, PMID: 25965369
Harnessing the immune system for the treatment of non-small-cell lung cancer, PMID: 23401435
Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559), PMID: 30747773
Immunotherapy in Lung Cancer: A New Age in Cancer Treatment, PMID: 30539506
The authors reply, PMID: 31415323
Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer, PMID: 23263823
Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy, PMID: 24917416
Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors, PMID: 24685885
Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer, PMID: 23714523
Saved From Sepsis: Can Immunotherapy Improve Acute and Postacute Outcomes?, PMID: 30985457
PD-1 and PD-L1 antibodies for melanoma, PMID: 25625924
Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy, PMID: 27796306
Programmed death-1 inhibition in renal cell carcinoma: clinical insights and future directions, PMID: 24892254
Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18 F-FDG PET/CT Imaging in Patients with Advanced Melanoma, PMID: 28360208
Understanding the structural and energetic basis of PD-1 and monoclonal antibodies bound to PD-L1: A molecular modeling perspective, PMID: 29203283
Immune Checkpoint Inhibitor Use in Sepsis: Monitoring Immune Checkpoint Inhibitor Toxicity, PMID: 31415322
Residue-specific binding mechanisms of PD-L1 to its monoclonal antibodies by computational alanine scanning, PMID: 34259259
SIRPα blockade therapy potentiates immunotherapy by inhibiting PD-L1+ myeloid cells in hepatocellular carcinoma., PMID:40523887
Pan-cancer analysis of TMED2: unraveling potential immune characteristics and prognostic value in cancer therapy., PMID:40519935
Myomedin variants developed for in vitro PD-L1 diagnostics in tissue samples of non-small cell lung carcinoma patients., PMID:40514707
Impact of PD‑L1 upregulation on immune checkpoint inhibitor efficacy in triple‑negative breast cancer using a 4T1 murine model., PMID:40511536
Agent-based modeling for personalized prediction of an experimental immune response to immunotherapeutic antibodies., PMID:40489506
Lenvatinib versus bevacizumab when combined with PD-1/L1 inhibitor and hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma., PMID:40486515
Efficacy of neoadjuvant, adjuvant, and perioperative immunotherapy in non-small cell lung cancer across different PD-L1 expression levels: a systematic review and meta-analysis., PMID:40463367
Targeted tumor cell-intrinsic CTRP6 biomimetic codelivery synergistically amplifies ferroptosis and immune activation to boost anti-PD-L1 immunotherapy efficacy in lung cancer., PMID:40457410
[Development of Antibody-polymer Conjugates for the Treatment of Intractable Cancers]., PMID:40451875
PD-L1 Expression in Biliary Tract Cancer: Comparison Across Antibody Clones and Role as a Predictor of Response to Chemoimmunotherapy: A Meta-Analysis., PMID:40440581
Positivity Rate of PD-L1 Expression and Its Clinical Significance in Vulvar Cancer: A Systematic Review and Meta-Analysis., PMID:40429739
Using liquid biopsies to guide treatment and monitor response in BRAF V600E positive adenocarcinoma of unknown primary., PMID:40425210
The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade., PMID:40416959
Antibody-dependent cellular cytotoxicity of anti-programmed death-ligand 1 antibodies for T cells attenuate their antitumor efficacy in a murine tumor model., PMID:40412452
Impact of rheumatoid factors on the function of therapeutic monoclonals specific for PD-1/PD-L1., PMID:40411581
Trop2, Nectin-4, and PD-L1 expression profiles in esophageal squamous cell carcinoma: Implications for combined immunotherapy and ADC targeted therapies., PMID:40403357
Molecular subtyping dictates therapeutic response to anti-PD-L1 immunotherapy in ES-SCLC., PMID:40402312
Real-world survival outcomes, treatment patterns, and impact of PD-L1 expression among patients with unresectable, stage III NSCLC treated with CRT → durvalumab in Canada: The RELEVANCE study., PMID:40393235
High-Sensitivity PD-L1 Staining Using Clone 73-10 Antibody and Spatial Transcriptomics for Precise Expression Analysis in Non-Tumorous, Intraepithelial Neoplasia, and Squamous Cell Carcinoma of Head and Neck., PMID:40392349
Inhibition of UCH-L1 enhances immunotherapy efficacy in triple-negative breast cancer by stabilizing PD-L1., PMID:40389130
Novel Pt@PCN-Cu-induced cuproptosis amplifies αPD-L1 immunotherapy in pancreatic ductal adenocarcinoma through mitochondrial HK2-mediated PD-L1 upregulation., PMID:40382627
Enhancing T cell cytotoxicity against lung cancer with an αPD-L1 protein engager and gemcitabine combination therapy., PMID:40381506
Chemotherapy elevates cell surface PD-L1 and MHC-I expression in apoptotic gastric cancer cells., PMID:40380807
Discovery of a New and Selective HPK1 PROTAC for Enhancing Tumor Immunotherapy through Eliminating GLK Degradation., PMID:40375722
Advances in cancer immunotherapy using small-molecular inhibitors targeting the PD-1/PD-L1 interaction., PMID:40367914
N-glycosylation of PD-L1 modulates the efficacy of immune checkpoint blockades targeting PD-L1 and PD-1., PMID:40346531
PD-L1 in plasmacytoid dendritic cells promote HBV persistence through disrupting humoral immune response., PMID:40342414
Blocking LIF and PD-L1 enhances the antitumor efficacy of SBRT in murine PDAC models., PMID:40341024
Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab., PMID:40334245
Biomarkers of response to antibody-drug conjugates (TROP2 and nectin-4) and the immune microenvironment (NKG7, PD-L1, and B7-H3) in penile squamous cell carcinoma., PMID:40327767
Cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced non-small cell lung cancer with programmed cell death-ligand 1 ≥50., PMID:40323717
Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG "PARCT"., PMID:40319676
Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy Compared with Chemotherapy as First-Line Treatment for Advanced PD-L1-Positive Triple-Negative Breast Cancer from a Japanese Healthcare Perspective., PMID:40317386
Spatial analysis identifies DC niches as predictors of pembrolizumab therapy in head and neck squamous cell cancer., PMID:40311615
Lactic acid inhibits the interaction between PD-L1 protein and PD-L1 antibody in the PD-1/PD-L1 blockade therapy-resistant tumor., PMID:40308191
Real-world comparison of pembrolizumab alone and combined with chemotherapy in metastatic lung adenocarcinoma patients with PD-L1 expression ≥50., PMID:40305908
A Multispecific Checkpoint Inhibitor Nanofitin with a Fast Tumor Accumulation Property and Anti-Tumor Activity in Immune Competent Mice., PMID:40305184
ERK2-mediated phosphorylation of ZEB1 at S322 enhances PD-L1 expression and EMT, leading to pancreatic cancer progression., PMID:40296122
Predictive value of EBV-positivity in patients with gastric cancer treated with first-line nivolumab plus chemotherapy., PMID:40295365
Improved overall survival in an anti-PD-L1 treated cohort of newly diagnosed glioblastoma patients is associated with distinct immune, mutation, and gut microbiome features: a single arm prospective phase I/II trial., PMID:40289138
N-deglycosylation targeting chimera (DGlyTAC): a strategy for immune checkpoint proteins inactivation by specifically removing N-glycan., PMID:40289109
Long-Term Outcomes in Patients with Locally Advanced and Metastatic Non-Small Cell Lung Cancer with High PD-L1 Expression., PMID:40277785
Synergistic Induction of Immunogenic Cell Death by Biomineralized Manganese and Bisphosphonates Enhances Anti-PD-L1 Therapy in Triple-Negative Breast Cancer., PMID:40276640
PD - L1 (SP263) expression correlates with pathological aggressive parameters in prostate cancer., PMID:40273724
Adeno-associated virus-clustered regularly interspaced short palindromic repeats/cas9‑mediated ovarian cancer treatment targeting PD-L1., PMID:40264105
Bispecific c-Met/PD-1 CAR-T Cells Have Enhanced Therapeutic Effects on Solid Tumor., PMID:40261343
Immunohistochemical expression of PD-L1 in colorectal carcinoma among black patients and the clinicopathological correlates: a cross-sectional study., PMID:40254571
Transient intracellular expression of PD-L1 and VEGFR2 bispecific nanobody in cancer cells inspires long-term T cell activation and infiltration to combat tumor and inhibit cancer metastasis., PMID:40253320
Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherapy., PMID:40252510
Durable response to nivolumab in combination with regional hyperthermia in a patient with PD-L1-negative metastatic head and neck squamous cell carcinoma., PMID:40244424
For research use only. Not for human or drug use.
